Overview

Study wants to explore real-world data in three distinct settings

• Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel _ARON-3S
• Patients receiving Lutetium-177 PSMA for mCRPC _ ARON-3Lu
• Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC _ ARON-3GEN

Eligibility

Inclusion Criteria:

• Patients aged >18y
• Cytological or Histologically confirmed diagnosis of PC
• Histologically or radiologically confirmed diagnosis of metastatic disease and

For ARON-3S

▪ Treatment with ADT + Apalutamide or ADT + enzalutamide or ADT + Abiraterone or ADT + Abiraterone + Docetaxel or ADT + Darolutamide + Docetaxel (patients treated with previous docetaxel - CHAARTED - resulted eligible)

For ARON-3Lu

▪ Treatment with Luthetium-177-PSMA therapy for castration resistant PC

For ARON-3GEN

• HRD POSITIVE STATUS
• Treatment with PARP inhibitors for castration resistant PC. Treatment included: olaparib (as 1st, 2nd or 3rd line therapy), olaparib + abiraterone (as 1st line therapy) or niraparib + abiraterone (as 1st line therapy) or talazoparib + enzalutamide

Exclusion Criteria:

• Patients without histologically confirmed diagnosis of PC
• Patients without histologically or radiologically confirmed metastatic disease and

For ARON-3S

▪ Patients treated with doublets or triplets not included in the list reported in the Inclusion Criteria Section

For ARON-3Lu

▪ Patients treated with Luthetium-177-PSMA therapy for hormone/castration sensitive PC

For ARON-3GEN

• HRD NEGATIVE STATUS
• Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study